As of September 30, Seres Therapeutics (MCRB) had $66.8M in cash and cash equivalents. The company expects to fund operations into Q4 of 2025.

To this end, we received notice last week from the FDA of Breakthrough Device Designation for the SCD in chronic dialysis. This is the fourth indication to receive this designation and the first for a ...

The FDA Modernization Act of 1997 established the Fast Track designation to expedite developing and reviewing new drugs ...

Plus, Donald Trump is set to visit the White House to meet with President Joe Biden for a symbolic meeting to signify a ...